Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

November 17, 2023

Study Completion Date

November 27, 2023

Conditions
Knee Osteoarthritis
Interventions
DRUG

Blinded study medication

Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.

Trial Locations (1)

21224

Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Johns Hopkins University

OTHER

NCT03098563 - Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis | Biotech Hunter | Biotech Hunter